BCLI Company Profile and Key Details
Brainstorm Cell Therapeutics Inc.
BCLI Stock Price Chart
Stock Price Today
Brainstorm Cell Therapeutics Inc. (BCLI) stock remained unchanged at $2.13 a share on NASDAQ. The stock opened at $2.20, fluctuating between $2.02 to $2.21 during the session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Company Information
| Employees | 29 |
| Beta | 0.39 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) stock price is $2.13 in the last trading session. During the trading session, BCLI stock reached the peak price of $2.21 while $2.02 was the lowest point it dropped to. The percentage change in BCLI stock occurred in the recent session was 0% while the dollar amount for the price change in BCLI stock was -.
The NASDAQ listed BCLI is part of Biotechnology industry that operates in the broader Healthcare sector. Brainstorm Cell Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Ralph Z. Kern
Pres & Chief Medical Officer
Mr. Chaim Lebovits
Chief Executive Officer
Ms. Mary Kay Turner
Senior Vice President of Patient Advocacy & Gov. Affairs
Ms. Alla Patlis CPA, M.B.A.
Controller & Interim Chief Financial Officer
Mr. Uri Yablonka
Executive Vice President, Chief Bus. Officer, Sec. & Director
Dr. Yael Gothelf
Vice President of Scientific & Regulatory Affairs
Dr. Irit Arbel DSc, Ph.D.
Co-Founder & Independent Vice Chair of the Board
Dr. David Setboun M.B.A., Pharm.D.
Executive Vice President & Chief Operating Officer
Ms. Antal Pearl-Lendner
Vice President & Chief Legal Counsel
Dr. Stacy R. Lindborg Ph.D.
Co-Chief Executive Officer
Dr. Daniel Offen Ph.D.
Chief Scientific Advisor
Dr. Ralph Z. Kern M.D., MHSc
Pres & Chief Medical Officer
Mr. William K. White
Senior Vice President & Head of Market Access and Pricing
BCLI's closing price is 102.86% higher than its 52-week low of $1.05 where as its distance from 52-week high of $11.85 is -82.03%.
Number of BCLI employees currently stands at 29.
Official Website of BCLI is: https://www.brainstorm-cell.com
BCLI could be contacted at phone 201 488 0460 and can also be accessed through its website. BCLI operates from 1325 Avenue of Americas, New York, NY 10019, United States.
BCLI stock volume for the day was 30.59K shares. The average number of BCLI shares traded daily for last 3 months was 108.61K.
The market value of BCLI currently stands at $12.15M with its latest stock price at $2.13 and 5.7M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com